Slingshot members are tracking this event:

Vertex (VRTX) Initiates Phase 2 Study Evaluating Triple Combination Dosing With VX-152 in ~35 CF Patients With One F508del Mutation and One Minimal Function Mutation and ~25 CF Patients with Two Copies of F508del.

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 25, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2, Initiation, Cystic Fibrosis Patients, F508del Mutation, Minimal Function Mutation